Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study- by Ebina, Kosuke et al.
Title
Drug retention and discontinuation reasons between seven
biologics in patients with rheumatoid arthritis -The ANSWER
cohort study-
Author(s)
Ebina, Kosuke; Hashimoto, Motomu; Yamamoto, Wataru;
Ohnishi, Akira; Kabata, Daijiro; Hirano, Toru; Hara, Ryota;
Katayama, Masaki; Yoshida, Shuzo; Nagai, Koji; Son, Yonsu;
Amuro, Hideki; Akashi, Kengo; Fujimura, Takanori; Hirao,
Makoto; Yamamoto, Keiichi; Shintani, Ayumi; Kumanogoh,
Atsushi; Yoshikawa, Hideki




© 2018 Ebina et al. This is an open access article distributed
under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction






Drug retention and discontinuation reasons
between seven biologics in patients with
rheumatoid arthritis -The ANSWER cohort
study-
Kosuke Ebina1*, Motomu Hashimoto2, Wataru Yamamoto2,3, Akira Ohnishi4,
Daijiro Kabata5, Toru Hirano6, Ryota Hara7, Masaki Katayama8, Shuzo Yoshida9,
Koji Nagai9, Yonsu Son10, Hideki Amuro10, Kengo Akashi4, Takanori Fujimura11,
Makoto Hirao1, Keiichi Yamamoto5, Ayumi Shintani5, Atsushi Kumanogoh6,
Hideki Yoshikawa1
1 Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan,
2 Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto
University, Kyoto, Japan, 3 Department of Health Information Management, Kurashiki Sweet Hospital,
Kurashiki, Japan, 4 Department of Rheumatology and Clinical Immunology, Kobe University Graduate
School of Medicine, Kobe, Japan, 5 Department of Medical Statistics, Osaka City University Graduate School
of Medicine, Osaka, Japan, 6 Department of Respiratory Medicine and Clinical Immunology, Osaka
University, Graduate School of Medicine, Osaka, Japan, 7 The Center for Rheumatic Diseases, Department
of Orthopaedic Surgery, Nara Medical University, Nara, Japan, 8 Department of Rheumatology, Osaka Red
Cross Hospital, Osaka, Japan, 9 Department of Internal Medicine (IV), Osaka Medical College, Osaka,
Japan, 10 First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 11 The Center
for Rheumatic Diseases, Nara Medical University, Nara, Japan
* k-ebina@umin.ac.jp
Abstract
The purpose of this study was to evaluate the retention and discontinuation reasons of
seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting
of patients with rheumatoid arthritis (RA). 1,037 treatment courses with bDMARDs from
2009 to 2016 [female, 81.8%; baseline age, 59.6 y; disease duration 7.8 y; rheumatoid fac-
tor positivity 81.5%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate
(DAS28-ESR), 4.4; concomitant prednisolone 43.5% and methotrexate 68.6%; Bio-naïve,
57.1%; abatacept (ABT), 21.3%; tocilizumab (TCZ), 20.7%; golimumab (GLM), 16.9%; eta-
nercept (ETN), 13.6%; adalimumab (ADA), 11.1%; infliximab (IFX), 8.5%; certolizumab
pegol (CZP), 7.9%] were included in this multi-center, retrospective study. Drug retention
and discontinuation reasons at 36 months were estimated using the Kaplan-Meier method
and adjusted by potent confounders using Cox proportional hazards modeling. As a result,
455 treatment courses (43.9%) were stopped, with 217 (20.9%) stopping due to inefficacy,
113 (10.9%) due to non-toxic reasons, 86 (8.3%) due to toxic adverse events, and 39
(3.8%) due to remission. Drug retention rates in the adjusted model were as follows: total
retention (ABT, 60.7%; ADA, 32.7%; CZP, 43.3%; ETN, 51.9%; GLM, 45.4%; IFX, 31.1%;
and TCZ, 59.2%; P < 0.001); inefficacy (ABT, 81.4%; ADA, 65.7%; CZP, 60.7%; ETN,
71.3%; GLM, 68.5%; IFX, 65.0%; and TCZ, 81.4%; P = 0.015), toxic adverse events (ABT,
89.8%; ADA, 80.5%; CZP, 83.9%; ETN, 89.2%; GLM, 85.5%; IFX, 75.6%; and TCZ, 77.2%;
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P = 0.50), and remission (ABT, 95.5%; ADA, 88.1%; CZP, 91.1%; ETN, 97.5%; GLM,
94.7%; IFX, 86.4%; and TCZ, 98.4%; P < 0.001). In the treatment of RA, ABT and TCZ
showed higher overall retention, and TCZ showed lower inefficacy compared to IFX, while
IFX showed higher discontinuation due to remission compared to ABT, ETN, GLM, and TCZ
in adjusted modeling.
Introduction
Biological disease-modifying antirheumatic drugs (bDMARDs) have dramatically improved
the management of rheumatoid arthritis (RA). Tumor necrosis factor inhibitors (TNFi) were
the first bDMARDs used for RA, and abundant evidence has been accumulated regarding the
efficacy, safety, and tolerability of adalimumab (ADA), etanercept (ETN), and infliximab (IFX)
[1–5]. On the other hand, other TNFi such as golimumab (GLM) (2011) and certolizumab
pegol (CZP) (2013) were lately licensed for RA in Japan. In addition, the European League
against Rheumatism (EULAR) announced a 2013 recommendation regarding the manage-
ment of RA with bDMARDs, in which tocilizumab (TCZ) and abatacept (ABT) were also con-
sidered as efficacious and safe as TNFi, which should be considered as a first-line biologic
agent [6]. However, clinicians’ choice of bDMARDs may depend on various factors (patients’
background characteristics such as age, comorbidities, combined conventional synthetic
DMARDs (csDMARDs), previously administered bDMARDs, economic burden, etc.) in clini-
cal practice, and reliable selection criteria for these bDMARDs are still lacking.
The adaptive criterion of randomized controlled trials (RCTs) is sometimes limited to
patients who are quite different from those in real-world settings [7], and observational studies
of cohort-based registries have increasingly been used to investigate the performance of
bDMARDs [1–4, 8–10]. In addition, drug retention in observational studies can be considered
as a composite measure and index of effectiveness, safety and tolerability [4, 11–13]. On the
other hand, treatment selection and discontinuation may be influenced by factors such as dif-
ferences in patient characteristics and attending physicians in observational studies, although
multi-center studies and the national health insurance in our country may help to diminish
these possible deviations [11–13].
The aim of this multi-center, retrospective study was to clarify the retention and reasons for
discontinuation of seven biologics in the real-world setting of RA.
Materials and methods
Patients
The Kansai Consortium for Well-being of Rheumatic Disease Patients (ANSWER) cohort is
an observational multi-center registry of patients with RA in the Kansai district of Japan. Data
of patients at seven institutes (Kyoto University, Osaka University, Osaka Medical College,
Kansai Medical University, Kobe University, Nara Medial University, and Osaka Red Cross
Hospital) were included. From 2011 to 2016, 4,461 patients with RA20 years were registered,
and 52,654 serial disease activities were available from the database. Data from patients with
RA treated using one of seven bDMARDs (ABT, ADA, CZP, ETN, GLM, IFX, and TCZ;
including both intravenous and subcutaneous agents, but excluding bio-similar agents, all of
which were introduced between January 2009 and September 2016) were retrospectively col-
lected. All patients with RA fulfilled the 1987 classification criteria of the American College of
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0194130 March 15, 2018 2 / 13
Funding: The authors received no specific funding
for this work.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: K.E., M.H., and H.Y.
have received research grants from Astellas,
Daiichi Sankyo, Eisai, and Mitsubishi Tanabe. K.E.
has received speaker fees from Abbvie, Astellas,
Asahi-Kasei, Daiichi Sankyo, Eli Lily, Eisai,
Mitsubishi Tanabe, Chugai, Ono Pharmaceutical,
and UCB Japan. M.H. is affiliated with a department
that is financially supported by four pharmaceutical
companies (Mitsubishi-Tanabe, Chugai, Ayumi,
and UCB Japan) and the city government
(Nagahama City). M.H. received a research grant
from Astellas. A.O. received a research grant from
Eisai, Asahi-Kasei Pharma, and Mitsubishi-Tanabe.
T.H. received a research grant and/or speaker fees
from Astellas, Chugai, Eisai, Mitsubishi Tanabe,
Abbvie, and Asahi-Kasei. A.S. has received speaker
fees from Chugai. A.K. received a research grant
and/or speaker fees from Acterion, Asahi Kasei,
Astellas, Chugai, Daiichi Sankyo, Eisai, Mitsubishi
Tanabe, Nippon Kayaku, Pfizer and Takeda. M.F.,
W.Y., D.K., T.F., R.H., M.K., K.A., S.Y., K.N., K.Y., Y.
S., H.A., and R.U. have no financial conflicts of
interest to disclose concerning this paper. This
does not alter our adherence to PLOS ONE policies
on sharing data and materials.
Rheumatology [14], and also had full baseline demographic data such as age, sex, disease activ-
ity (Disease Activity Score in 28 joints using erythrocyte sedimentation rate [DAS28-ESR]),
disease duration of RA, number of previously administered bDMARDs, reasons for discontin-
uation of bDMARDs, dates of both starting and discontinuing bDMARDs, concomitant doses
of MTX and PSL, and presence of other csDMARDs for which evidence has been accumulated
to enhance the efficacy of bDMARDs, such as bucillamine (BUC) [15, 16], iguratimod (IGU)
[17], salazosulfapyridine (SASP) [16, 18], and tacrolimus (TAC) [19, 20]. Patients without data
for these parameters were excluded. Other baseline demographic features such as rheumatoid
factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) positivity, and Health
Assessment Questionnaire [HAQ] disability index [DI] score were also collected.
Treatments were administered by the attending rheumatologists in accordance with guide-
lines of the Japan College of Rheumatology. Drug retention was retrospectively evaluated as
the duration until definitive treatment interruption. Reasons for discontinuation of biologics
were analyzed and classified into four major categories: 1) inefficacy (including primary and
secondary); 2) remission; 3) toxic adverse events (infection, skin or systemic reaction, and
other toxic events [including hematologic, pulmonary, renal, cardiovascular complications
and malignancies]; and 4) nontoxic reasons (patient preference, change in hospital, desire for
pregnancy, etc.). Physicians were allowed to cite only one reason for discontinuation. The rep-
resentative facility of this registry is Kyoto University, and this observational study (not clinical
trial) was conducted in accordance with the Declaration of Helsinki (results are not published
elsewhere), and approved by each ethics committee of seven institutes (Kyoto University,
Osaka University, Osaka Medical College, Kansai Medical University, Kobe University, Nara
Medial University, and Osaka Red Cross Hospital). In addition, the detail of this study is
shown in the homepage of Osaka University Graduate School of Medicine (approval number;
15300), and written informed consent was obtained from all participants prior to enrollment.
Statistical analysis
Baseline characteristics were compared across the seven bDMARDs. The significance of differ-
ences was assessed using the Kruskal-Wallis nonparametric test for continuous variables and
Pearson’s chi-square test for categorical variables. The survival curves of each biologic explained
by specific causes were examined by the Kaplan-Meier method and compared statistically using
a stratified log-rank test. The time to discontinuation of biologics was analyzed using Cox pro-
portional hazards modeling [1]. The proportion of treatment discontinuation explained by spe-
cific causes were analyzed at 36 months, and also adjusted by potential confounders that may
influence drug discontinuation and the incidence of adverse events, as previously described
(sex, baseline age, disease duration, DAS28-ESR, HAQ-DI, RF and ACPA positivity, concomi-
tant MTX and PSL dose, presence of concomitant csDMARDs (BUC, IGU, SASP, and TAC),
date of starting bDMARDs, and number of previously administered bDMARDs) [1, 8–10, 21].
Multivariate Cox proportional modeling was designed using stepwise backward deletion in
choosing those covariates showing values of P< 0.05 for adjustment.
Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical Uni-
versity, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical
Computing, Vienna, Austria) [22]. P< 0.05 were considered statistically significant.
Results
Baseline characteristics
The study population was selected from all patients with RA in the ANSWER cohort
(n = 4461) who fulfilled the inclusion criteria (n = 750; 1037 bDMARD treatment courses).
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis
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Baseline demographic and clinical characteristics of the enrolled patients (ABT, n = 221; ADA,
n = 115; CZP, n = 82; ETN, n = 141; GLM, n = 175; IFX, n = 88; TCZ, n = 215) are described
in Table 1. Overall at baseline, mean age was 59.6 years, 81.8% of participants were female,
mean disease duration was 7.8 years, RF positivity was 81.5%, ACPA positivity was 86.7%,
mean DAS28-ESR score was 4.4, and mean HAQ-DI score was 1.1. In addition, concomitant
medications were PSL in 43.5%, MTX in 68.6%, SASP in 23.3%, BUC in 10.0%, TAC in 6.8%,
and IGU in 2.0%. The bDMARD being administered was the first in 57.1%, second in 24.0%
and third or more in 18.9%.
Between the seven bDMARDs, no significant differences were observed in baseline sex, RF
or ACPA positivity, DAS28-ESR, or HAQ-DI. On the other hand, significant differences were
observed in baseline age (P< 0.001), disease duration (P< 0.001), PSL usage (%) (P = 0.025),
PSL dose (mg/day) (P = 0.005), MTX usage (%) (P< 0.001), MTX dose (mg/week) (P< 0.001),
SASP usage (%) (P< 0.001), BUC usage (%) (P = 0.027), TAC usage (%) (P< 0.001), and num-
ber of previously administered bDMARDs (P< 0.001).
Drug retention
Overall, 455 treatment courses (43.9%) were stopped by 36 months. A total of 217 (20.9%)
were stopped due to inefficacy, 113 (10.9%) due to non-toxic reasons [34 (3.3%) due to patient
preference, 23 (2.2%) due to change in hospital, 56 (5.4%) due to other nontoxic reasons], 86
Table 1. Clinical characteristics at initiation of each biologic agent.
Variable ABT (n = 221) ADA (n = 115) CZP (n = 82) ETN (n = 141) GLM (n = 175) IFX (n = 88) TCZ (n = 215) P-value
Age (years) 64.4±11.7 55.1±12.8 56.4±17.1 58.6±15.2 61.4±14.3 55.3±13.2 58.9±14.1 <0.001
Female sex (%) 80.5 78.3 87.8 85.1 87.4 76.1 78.1 0.067
Disease duration (years) 8.9±10.1 4.0±5.9 5.8±8.0 8.4±10.2 10.7±11.4 3.6±6.4 8.8±9.0 <0.001
RF positivity (%) 87.2 79.3 83.3 79.8 83.8 73.2 79.1 0.2
ACPA positivity (%) 88.1 88.2 88.4 89.1 85.3 81.7 85.9 0.77
DAS28-ESR 4.4±1.3 4.2±1.2 4.6±1.5 4.4±1.5 4.3±1.3 4.5±1.6 4.6±1.5 0.19
HAQ-DI 1.2±0.8 0.9±0.7 1.1±0.9 0.9±0.8 1.1±0.9 1.1±0.9 1.2±0.8 0.16
PSL usage (%) 48.4 33 45.1 41.1 42.3 34.1 49.8 0.025
PSL dose (mg/day) 3.2±6.9 1.7±3.1 2.8±4.2 2.2±3.3 2.1±2.9 1.6±2.7 3.1±4.1 0.005
MTX usage (%) 56.1 89.6 72 59.6 70.9 95.5 61.9 <0.001
MTX dose (mg/week) 4.4±4.5 8.5±4.1 6.4±4.8 5.2±4.8 5.9±4.5 8.9±4.0 5.2±4.7 <0.001
SASP usage (%) 33.5 22.6 25.6 22.7 24.6 13.6 15.8 <0.001
BUC usage (%) 14.9 7.8 4.9 10.6 12.6 4.5 7.9 0.027
TAC usage (%) 14.5 2.6 4.9 2.1 5.1 3.4 7.4 <0.001
IGU usage (%) 1.8 0.9 1.2 2.1 2.3 1.1 3.3 0.89
1st bio (%) 63.8 77.4 58.5 63.1 41.1 83 37.2 <0.001
2nd bio (%) 19.9 16.5 15.9 20.6 35.4 10.2 34 <0.001
≧3rd bio (%) 16.3 6.1 25.6 16.3 23.5 6.8 28.8 <0.001
Values represent mean ± standard error (SE), unless otherwise noted. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept,
GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, RF = rheumatoid factor, ACPA = anti-cyclic citrullinated peptide antibody, DAS28-ESR = Disease Activity
Score in 28 joints using erythrocyte sedimentation rate, HAQ-DI = Health Assessment Questionnaire disability index, PSL = prednisolone, MTX = methotrexate,
SASP = salazosulfapyridine, BUC = bucillamine, TAC = tacrolimus, IGU = iguratimod. Bio = biologic agent.
The significance of differences was assessed using the Kruskal-Wallis nonparametric test for continuous variables and Pearson’s chi-square test for categorical variables.
https://doi.org/10.1371/journal.pone.0194130.t001
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(8.3%) due to toxic reasons [34 (3.3%) due to infection, 28 (2.7%) due to other adverse events
such as hematological, pulmonary, renal, or cardiovascular complications or malignancy, and
24 (2.3%) due to skin or systemic reaction], and 39 (3.8%) due to remission.
Total drug retention rates were analyzed using Kaplan-Meier estimates in both the non-
adjusted model (Fig 1A) and adjusted model for potent cofounders using Cox proportional
hazards regression modeling (Fig 1B). At 36 months, drug retention rates were as follows: 1)
non-adjusted model: ABT (59.4%), ADA (36.8%), CZP (41.2%), ETN (51.6%), GLM (44.7%),
IFX (35.7%), and TCZ (54.7%) (log-rank P = 0.006), and 2) adjusted model: ABT (60.7%),
ADA (32.7%), CZP (43.3%), ETN (51.9%), GLM (45.4%), IFX (31.1%), and TCZ (59.2%) (Cox
P< 0.001). Of note, treatment with ABT (Cox P = 0.0002) and TCZ (Cox P = 0.0009) showed
significantly higher persistency compared to IFX in the adjusted model. Concerning other
confounders, combined MTX dose (hazard ratio (HR) = 0.96, 95% confidence interval (CI) =
0.94–0.98, P = 0.0002) and TAC (HR = 0.63, 95%CI = 0.41–0.97, P = 0.036) at baseline showed
positive effects, while combined PSL dose (HR = 1.02, 95%CI = 1.01–1.04, P = 0.0038), female
sex (HR = 1.33, 95%CI = 1.06–1.69, P = 0.016), and number of previously administered
bDMARDs (HR = 1.13, 95%CI = 1.04–1.22, P = 0.0031) at baseline showed negative effects on
total drug retention.
Causes of discontinuation
Cause-specific cumulative discontinuation rates were assessed using Kaplan-Meier estimates
in both non-adjusted and adjusted models for potent cofounders using Cox proportional
Fig 1. Overall drug survival rates of (a) non-adjusted and (b) adjusted cases. Adjusted confounder s were baseline sex, age, disease duration, DAS28-ESR,
HAQ-DI, RF and ACPA positivity, concomitant MTX and PSL dose, presence of concomitant csDMARDs (BUC, IGU, SASP, and TAC), date of starting
bDMARDs, and number of previously used bDMARDs.ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM =
golimumab, IFX = infliximab, TCZ = tocilizumab, DAS28-ESR = Disease Activity Score in 28 joints using erythrocyte sedimentation rate, HAQ-DI = Health
Assessment Questionnaire disability index, RF = rheumatoid factor, ACPA = anti- cyclic citrullinated peptide antibody, MTX = methotrexate, PSL = pre-
dnisolone, csDMARDs = conventional synthetic disease-modifying antirheumatic drugs, BUC = bucillamine, IGU = iguratimod, SASP = salazosulfa-
pyridine, TAC = tacrolimus, bDMARDs = biological disease-modifying antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0194130.g001
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hazards regression modeling (Figs 2–4). At 36 months, drug retention rates due to inefficacy
(Fig 2) were as follows: 1) non-adjusted model; ABT (81.0%), ADA (68.6%), CZP (56.5%),
ETN (72.0%), GLM (65.9%), IFX (68.8%), and TCZ (78.6%) (log-rank P = 0.093) (Fig 2A); and
2) adjusted model; ABT (81.4%), ADA (65.7%), CZP (60.7%), ETN (71.3%), GLM (68.5%),
IFX (65.0%), and TCZ (81.4%) (Cox P = 0.015) (Fig 2B).
Drug persistency rates due to all toxic adverse events (Fig 3) were as follows: 1) non-
adjusted model; ABT (90.5%), ADA (81.3%), CZP (86.3%), ETN (86.6%), GLM (81.5%), IFX
(81.9%), and TCZ (79.3%) (log-rank P = 0.40) (Fig 3A); and 2) adjusted model; ABT (89.8%),
ADA (80.5%), CZP (83.9%), ETN (89.2%), GLM (85.5%), IFX (75.6%), and TCZ (77.2%) (Cox
P = 0.67) (Fig 3B).
Drug persistency rates due to remission (Fig 4) were as follows: 1) non-adjusted model;
ABT (94.7%), ADA (82.9%), CZP (89.5%), ETN (97.2%), GLM (94.7%), IFX (78.0%), and TCZ
(98.0%) (log-rank P < 0.001) (Fig 4A); and 2) adjusted model; ABT (95.5%), ADA (88.1%),
CZP (91.1%), ETN (97.5%), GLM (94.7%), IFX (86.4%), and TCZ (98.4%) (Cox P < 0.001)
(Fig 4B). The number at risk of each bDMARD is shown in S1 Table.
Hazard ratios (HRs) of discontinuation due to each specific cause were calculated using
multivariate Cox proportional hazards regression modeling (Table 2). HRs for discontinuation
due to overall causes were significantly lower in ABT [HR = 0.50, 95%CI = 0.34–0.73,
P<0.001] and TCZ (HR = 0.54, 95%CI = 0.37–0.79, P = 0.0014) compared to IFX, and signifi-
cant differences were seen between the seven bDMARDs (P<0.001). In terms of HRs for
Fig 2. Drug survival rates due to inefficacy of (a) non-adjusted and (b) adjusted cases. Adjusted confounder s were baseline sex, age, disease
duration, DAS28-ESR, HAQ-DI, RF and ACPA positivity, concomitant MTX and PSL dose, presence of concomitant csDMARDs (BUC, IGU,
SASP, and TAC), date of starting bDMARDs, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP =
certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, DAS28-ESR = Disease Activity Score in 28 joints
using erythrocyte sedimentation rate, HAQ-DI = Health Assessment Questionnaire disability index, RF = rheumatoid factor, ACPA = anti- cyclic
citrullinated peptide antibody, MTX = methotrexate, PSL = prednisolone, csDMARDs = conventional synthetic disease-modifying antirheumatic
drugs, BUC = bucillamine, IGU = iguratimod, SASP = salazosulfapyridine, TAC = tacrolimus, bDMARDs = biological disease-modifying
antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0194130.g002
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discontinuation due to inefficacy, TCZ showed a significantly lower rate compared to IFX
(HR = 0.56, 95%CI = 0.31–0.98, P = 0.043), and the difference was significant between the seven
bDMARDs (P = 0.015). No significant difference was observed in HRs for discontinuation due
to all toxic adverse events, including infection and systemic or skin reaction. However, ABT
showed significantly lower HRs for other toxic events such as hematological, pulmonary, renal,
cardiovascular complications and malignancy (HR = 0.24, 95%CI = 0.06–0.92, P = 0.037) com-
pared to IFX, and the difference was significant between the seven bDMARDs (P = 0.0089). On
the other hand, IFX showed higher HRs for remission compared to ABT (HR = 0.12, 95%
CI = 0.03–0.45, P = 0.0015), ETN (HR = 0.14, 95%CI = 0.03–0.62, P = 0.0098), GLM
(HR = 0.33, 95%CI = 0.11–0.98, P = 0.046), and TCZ (HR = 0.13, 95%CI = 0.03–0.46,
P = 0.0017), and the difference was significant between the seven bDMARDs (P<0.001).
Discussion
In this study, ABT and TCZ showed higher overall retention rates, TCZ showed lower ineffi-
cacy rates, and ABT showed lower toxic events (excluding infection and systemic or skin reac-
tion) rates compared to IFX, while IFX showed higher discontinuation rates due to remission
compared to ABT, ETN, GLM, and TCZ, after adjusting for potential confounders.
Concerning TNFi, previous reports have demonstrated that the largest reason for discon-
tinuation was inefficacy (55.8%) [1], and ETN showed a higher retention rate compared to
ADA and IFX [1, 3, 5], which correspond to our results.
Fig 3. Drug survival rates due to toxic adverse events of (a) non-adjusted and (b) adjusted cases. Adjusted confounder s were baseline sex, age,
disease duration, DAS28-ESR, HAQ-DI, RF and ACPA positivity, concomitant MTX and PSL dose, presence of concomitant csDMARDs (BUC,
IGU, SASP, and TAC), date of starting bDMARDs, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP =
certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, DAS28-ESR = Disease Activity Score in 28 joints
using erythrocyte sedimentation rate, HAQ-DI = Health Assessment Questionnaire disability index, RF = rheumatoid factor, ACPA = anti- cyclic
citrullinated peptide antibody, MTX = methotrexate, PSL = prednisolone, csDMARDs = conventional synthetic disease-modifying antirheumatic
drugs, BUC = bucillamine, IGU = iguratimod, SASP = salazosulfapyridine, TAC = tacrolimus, bDMARDs = biological disease-modifying
antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0194130.g003
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With respect to biologics of non-TNFi, we have previously reported that TCZ and ETN
showed higher retention, and TCZ showed lower inefficacy compared to ADA and IFX [23].
Kubo et al. showed that ABT and TCZ showed similar retention (ABT 72%, TCZ 69%) and
remission rate (ABT 18%, TCZ 20%) after adjustment by propensity score matching at 52
weeks [24]. In addition, in TNFi failure patients, ABT and TCZ showed similar retention
(ABT 54%, TCZ 64%) and a good-or-moderate EULAR response (ABT 77%, TCZ 84%) at 48
weeks [25]. Another report also showed that in patients with first TNFi failure, switching to
non-TNFi-bDMARDs showed higher retention rate compared to switching to second-TNFi
after adjustment for propensity scores [8]. Collectively, TCZ and ABT may exhibit higher
retention rates compared to other TNFi in both bio-naïve and bio-switched patients in routine
care.
In reference to treatment holiday due to remission of bDMARDs, previous reports have
demonstrated that IFX and ADA seem to have better potential for discontinuation compared
to CZP or ETN, as shown in the BeSt, HIT HARD, and OPTIMA studies in early RA, and in
the RRR and HONOR studies in established RA [26–33], which agree with our result. How-
ever, these previous reports may have influenced the decisions regarding discontinuation by
each physician, and further study is required to compare the maintenance of bDMARD-free
remission between these agents.
Factors affecting bDMARDs retention and response have been reported. Female sex [5],
concomitant PSL [3], high DAS28 or HAQ [3, 9, 34], absence or low dose of combined MTX
Fig 4. Drug survival rates due to remission of (a) non-adjusted and (b) adjusted cases. Adjusted confounder s were baseline sex, age, disease
duration, DAS28-ESR, HAQ-DI, RF and ACPA positivity, concomitant MTX and PSL dose, presence of concomitant csDMARDs (BUC, IGU, SASP,
and TAC), date of starting bDMARDs, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol,
ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, DAS28-ESR = Disease Activity Score in 28 joints using erythrocyte
sedimentation rate, HAQ-DI = Health Assessment Questionnaire disability index, RF = rheumatoid factor, ACPA = anti- cyclic citrullinated peptide
antibody, MTX = methotrexate, PSL = prednisolone, csDMARDs = conventional synthetic disease-modifying antirheumatic drugs, BUC =
bucillamine, IGU = iguratimod, SASP = salazosulfapyridine, TAC = tacrolimus, bDMARDs = biological disease-modifying antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0194130.g004
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[3, 9], and number of previous bDMARDs [9] were negative predictors, while concomitant
use of csDMARDs besides MTX was a positive predictor of retention [5], which correspond
with our results.
In this study, baseline DAS28-ESR and HAQ-DI did not show significant influences on
total drug retention, maybe due to uniformity of these parameters between agents. On the
other hand, combined dose of MTX and presence of TAC showed positive effects, while com-
bined PSL dose showed negative effects on total drug retention in this study, suggesting the
impact of these factors in both TNFi and non-TNFi retention.
Regarding to the efficacy of low-dose MTX in Japanese compared to Western populations,
intraerythrocyte MTX-polyglutamate (MTX-PG) concentrations, which have been suggested
as a useful biomarker of efficacy, reached 94 nmol/L at 10.3 mg/week of MTX in Japanese,
compared to 65 nmol/L at 13.4 mg/week of MTX in the United States [35]. As a result, a rela-
tively low dose of MTX may exhibit positive effects on bDMARDs retention in Japanese com-
pared to Western populations. Previous studies have demonstrated that the efficacy of
bDMARDs is enhanced by combination with csDMARDs such as BUC [15, 16], IGU [17],
SASP [16, 18], and TAC [19, 20]. However, only TAC showed significant effects, and the
effects of other csDMARDs were relatively marginal when adjusted by other confounders.
Finally, bDMARDs retention in both non-adjusted and adjusted models by these possible con-
founders were evaluated. The tendencies were similar in both models in general, suggesting
the predominance of the difference of bDMARDs in drug retention.
Table 2. Causes of treatment discontinuation at 36 months (Cox proportional hazards model, adjusted analysis).
Reference HR (95%CI)
Variable IFX ABT ADA CZP ETN GLM TCZ P-value









0.71 (0.48–1.05) 0.86 (0.59–1.24) 0.54 (0.37–0.79) <0.001




0.99 (0.55–1.80) 1.21 (0.70–2.11) 0.56 (0.31–0.98) 0.015




0.73 (0.33–1.64) 0.85 (0.39–1.83) 0.90 (0.44–1.84) 0.67




1.59 (0.41–6.17) 0.61 (0.12–3.06) 0.71 (0.17–2.98) 0.78




0.64 (0.16–2.60) 0.32 (0.06–1.77) 0.42 (0.10–1.69) 0.6




0.34 (0.08–1.41) 1.29 (0.42–4.03) 1.02 (0.33–3.13) 0.0089




1.17 (0.45–3.05) 0.79 (0.28–2.19) 0.73 (0.27–1.91) 0.37











HR = hazard ratio; 95%CI = 95% confidence interval, IFX = infliximab, ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept,
GLM = golimumab, TCZ = tocilizumab.
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Some limitations to this study need to be considered. The number of patients was relatively
small, as we only recruited patients who fulfilled the clinical backgrounds data, which may
affect bDMARDs retention. However, this may also be a strength of this study. Second, the
judgment and reasons for discontinuation depended on the decisions of each physician, with-
out standardized criteria. Third, this was a retrospective study and the backgrounds of patients
differed between the agents. Fourth, the minor dose changes of csDMARDs and PSL during
the treatment period could not be monitored. However, the strength of this study was that
treatment choice and discontinuation judgments were based on a real-world setting, and also
the novelty of a trial to evaluate retention rates and discontinuation reasons for these seven
bDMARDs.
Conclusions
ABT and TCZ showed higher overall retention, TCZ showed lower inefficacy compared to
IFX, while IFX showed higher discontinuation due to remission compared to ABT, ETN,
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